45 results on '"Puliyanda D"'
Search Results
2. 341 A phase i/ii, double-blind, placebo-controlled study assessing safety and efficacy of c1 esterase inhibitor for prevention of delayed graft function in recipients of deceased donor kidney transplant
3. NR1I2 8055 Gene Polymorphism of Pregnane X Nuclear Receptor Is Not a Risk Factor for Polyomavirus BK (BKV) Infection in HLA-Sensitized (HS) Patients Transplanted After Desensitization With IVIG and Rituximab.: Abstract# B1006
4. Incidence and Severity of CMV Viremia After Desensitization With IVIG + Rituximab (RIT).: Abstract# A167
5. Tocilizumab (Anti-IL6-Receptor) Therapy For Donor-Specific Antibody (DSA+) Antibody Mediated Rejection (ABMR+) Resistant To IVIG + Rituxan Treatment.: Abstract# 2249
6. Response to corticosteroid treatment in paediatric nephrotic syndrome: A retrospective review from Mozambique
7. The Presence of De Novo Donor Specific Anti-HLA Antibody Is Associated with Medication Nonadherence and Allograft Loss in Pediatric Renal Transplant Recipients.: Abstract# 977 Poster Board #-Session: P142-II
8. Incidence and Severity of BK Viremia (BKV) after Desensitization with IVIG + Rituximab (RIT).: Abstract# 285
9. Variables affecting estimated glomerular filtration rate after renal transplantation in children: A NAPRTCS data analysis
10. The onset of rapidly progressive neurologic deterioration after a brief gastrointestinal illness in a renal allograft recipient
11. Younger Age and Antibody Induction Increase the Risk for Infection in Pediatric Renal Transplantation: A NAPRTCS Report
12. Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient
13. MON-022 STEROID RESISTANCE IN CHILDHOOD NEPHROTIC SYNDROME IN MAPUTO, MOZAMBIQUE
14. Letter to Editor:HIVmedicine
15. Incidence and Severity of CMV Viremia After Desensitization With IVIG + Rituximab (RIT).
16. Tocilizumab (Anti-IL6-Receptor) Therapy For Donor-Specific Antibody (DSA+) Antibody Mediated Rejection (ABMR+) Resistant To IVIG + Rituxan Treatment.
17. NR1I2 8055 Gene Polymorphism of Pregnane X Nuclear Receptor Is Not a Risk Factor for Polyomavirus BK (BKV) Infection in HLA-Sensitized (HS) Patients Transplanted After Desensitization With IVIG and Rituximab.
18. Variables affecting estimated glomerular filtration rate after renal transplantation in children: A NAPRTCS data analysis
19. 407 DETECTION OF CYTOMEGALOVIRUS-SPECIFIC CYTOTOXIC T-CELLS IN TRANSPLANT RECIPIENTS USING THE CYTOKINE FLOW CYTOMETRY ASSAY.
20. DETECTION OF CYTOMEGALOVIRUS-SPECIFIC CYTOTOXIC T-CELLS IN TRANSPLANT RECIPIENTS USING THE CYTOKINE FLOW CYTOMETRY ASSAY.
21. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients1
22. Detection of Cytomegalovirus-Specific Cytotoxic T-Cells in Transplant Recipients Using the Cytokine Flow Cytometry Assay
23. Passive immunization against cytomegalovirus during pregnancy.
24. Letter to Editor: HIV medicine.
25. Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium.
26. Antibody-mediated rejection in pediatric kidney transplant recipients: A report from the Pediatric Nephrology Research Consortium.
27. Utilization of SARS-CoV-2-Positive donors in pediatric renal transplantation.
28. Failure to thrive in an 8-month-old female: Answers.
29. Failure to thrive in an 8-month-old female: Questions.
30. Children Are Not Small Adults: Similarities and Differences in Renal Transplantation Between Adults and Pediatrics.
31. Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients.
32. Development of CMV-specific cytotoxic T cells (CMV-Tc) in pediatric renal transplant recipients with CMV viremia.
33. A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients.
34. Collagen type III glomerulopathy.
35. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
36. Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients.
37. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.
38. A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients.
39. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
40. The effects of everolimus on tuberous sclerosis-associated lesions can be dramatic but may be impermanent.
41. The authors' reply.
42. Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIG and rituximab.
43. Induction therapy in pediatric renal transplant recipients: an overview.
44. Cellular immune responses to cytomegalovirus in renal transplant recipients.
45. Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.